MA40137A1 - Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement - Google Patents
Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellementInfo
- Publication number
- MA40137A1 MA40137A1 MA40137A MA40137A MA40137A1 MA 40137 A1 MA40137 A1 MA 40137A1 MA 40137 A MA40137 A MA 40137A MA 40137 A MA40137 A MA 40137A MA 40137 A1 MA40137 A1 MA 40137A1
- Authority
- MA
- Morocco
- Prior art keywords
- hla molecules
- absolute quantification
- cancer peptides
- peptides restricted
- molecules naturally
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 238000011002 quantification Methods 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 238000011230 antibody-based therapy Methods 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000013459 approach Methods 0.000 abstract 1
- 238000011161 development Methods 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 229940023041 peptide vaccine Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000012546 transfer Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
La présente invention se rapporte à un procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement, à savoir la détermination du nombre de copies d'un ou de plusieurs peptides tel que présenté par cellule. La présente invention peut non seulement être utilisée pour le développement des traitements par anticorps ou des vaccins peptidiques mais est également très précieuse pour une immunosurveillance dont la composition moléculaire a été définie, et utile dans les procédés d'identification de nouveaux antigènes peptidiques pour des stratégies immunothérapeutiques, telles que des vaccins respectifs, des thérapies à base d'anticorps ou des approches de transfert adoptif de lymphocytes t dans la lutte contre le cancer et/ou les maladies auto-immunes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1423361.3A GB201423361D0 (en) | 2014-12-30 | 2014-12-30 | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| PCT/EP2015/079873 WO2016107740A1 (fr) | 2014-12-30 | 2015-12-15 | Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA40137A1 true MA40137A1 (fr) | 2018-03-30 |
| MA40137B1 MA40137B1 (fr) | 2019-05-31 |
Family
ID=52471641
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41287A MA41287B1 (fr) | 2014-12-30 | 2015-12-15 | Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement |
| MA40137A MA40137B1 (fr) | 2014-12-30 | 2015-12-15 | Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41287A MA41287B1 (fr) | 2014-12-30 | 2015-12-15 | Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US10545154B2 (fr) |
| EP (1) | EP3241026B1 (fr) |
| JP (1) | JP6735741B2 (fr) |
| KR (1) | KR102336968B1 (fr) |
| CN (1) | CN107003322B (fr) |
| AU (1) | AU2015373584B2 (fr) |
| BR (1) | BR112017008212B1 (fr) |
| CA (1) | CA2972306C (fr) |
| CL (1) | CL2017001071A1 (fr) |
| CO (1) | CO2017004543A2 (fr) |
| CR (1) | CR20170297A (fr) |
| CY (1) | CY1124223T1 (fr) |
| DK (1) | DK3241026T3 (fr) |
| EA (1) | EA036328B1 (fr) |
| ES (1) | ES2871035T3 (fr) |
| GB (1) | GB201423361D0 (fr) |
| HR (1) | HRP20210811T1 (fr) |
| HU (1) | HUE054455T2 (fr) |
| IL (1) | IL250982B (fr) |
| LT (1) | LT3241026T (fr) |
| MA (2) | MA41287B1 (fr) |
| MD (1) | MD3241026T2 (fr) |
| MX (1) | MX383806B (fr) |
| MY (1) | MY190199A (fr) |
| PE (1) | PE20171136A1 (fr) |
| PH (1) | PH12017500483A1 (fr) |
| PL (1) | PL3241026T3 (fr) |
| PT (1) | PT3241026T (fr) |
| RS (1) | RS61914B1 (fr) |
| SG (2) | SG11201703841VA (fr) |
| SI (1) | SI3241026T1 (fr) |
| TW (1) | TWI632370B (fr) |
| UA (1) | UA122774C2 (fr) |
| WO (1) | WO2016107740A1 (fr) |
| ZA (1) | ZA201701646B (fr) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| MY190083A (en) * | 2015-03-17 | 2022-03-25 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| MY198087A (en) | 2015-10-05 | 2023-07-31 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| EP4317432A3 (fr) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | Récepteurs de lymphocytes t à appariement amélioré |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| PT3428194T (pt) | 2017-07-14 | 2021-11-18 | Immatics Biotechnologies Gmbh | Molécula de polipéptido com especificidade dupla melhorada |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| JP7470640B2 (ja) * | 2018-02-09 | 2024-04-18 | イマティクス ユーエス，アイエヌシー． | Ｔ細胞を製造する方法 |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| KR102731127B1 (ko) | 2018-09-05 | 2024-11-18 | 에스케이하이닉스 주식회사 | 메모리 컨트롤러 및 이를 포함하는 메모리 시스템 |
| TW202039535A (zh) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
| WO2020191172A1 (fr) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cultures de cellules t cd28, leurs compositions et leurs méthodes d'utilisation |
| MA56036A (fr) | 2019-05-27 | 2022-04-06 | Immatics Us Inc | Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive |
| US20200384028A1 (en) | 2019-06-06 | 2020-12-10 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| JP2022543687A (ja) | 2019-08-09 | 2022-10-13 | イマティクス ユーエス，アイエヌシー． | ペプチド質量分析断片化を予測するための方法 |
| US12480958B2 (en) * | 2019-08-13 | 2025-11-25 | Immatics Biotechnologies Gmbh | Method for the characterization of peptide:MHC binding polypeptides |
| AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| US12312412B2 (en) | 2020-05-19 | 2025-05-27 | Amgen Inc. | MAGEB2 binding constructs |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| PE20250846A1 (es) | 2020-12-31 | 2025-03-21 | Immatics Us Inc | Polipeptidos cd8, composiciones y metodos de uso de estos |
| BR112023022765A2 (pt) | 2021-05-05 | 2024-01-02 | Immatics Biotechnologies Gmbh | Proteínas de ligação ao antígeno que ligam especificamente o prame |
| BR112023022975A2 (pt) | 2021-05-05 | 2024-01-23 | Immatics Biotechnologies Gmbh | Polipeptídeos de ligação ao antígeno bma031 melhorados |
| US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| EP4113120A1 (fr) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Procédé de caractérisation des caractéristiques de liaison entre un peptide d'intérêt et des molécules du cmh |
| JP2024529467A (ja) | 2021-07-27 | 2024-08-06 | イマティクス バイオテクノロジーズ ゲーエムベーハー | Ｃｔ４５に特異的に結合する抗原結合タンパク質 |
| JP2024534825A (ja) | 2021-08-24 | 2024-09-26 | イマティクス ユーエス，アイエヌシー． | 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択 |
| WO2023044488A1 (fr) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Déplétion monocytaire des populations de lymphocytes t pour une thérapie par lymphocytes t |
| EP4408468A4 (fr) | 2021-09-28 | 2025-07-02 | Frontaim Biomedicines Inc | Formats multiples de complexes moléculaires |
| US20230190806A1 (en) | 2021-10-06 | 2023-06-22 | Immatics Biotechnologies Gmbh | Methods of treating metastatic lesions and compositions thereof |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| IL316515A (en) | 2022-04-28 | 2024-12-01 | Immatics Us Inc | Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use |
| EP4514821A1 (fr) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Polypeptides d'il-12, polypeptides d'il-15, polypeptides d'il-18, polypeptides de cd8, compositions et leurs procédés d'utilisation |
| EP4514834A1 (fr) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Polypeptides récepteurs de tgfbêta négatifs dominants, polypeptides cd8, cellules, compositions et leurs méthodes d'utilisation |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| WO2025008513A1 (fr) | 2023-07-05 | 2025-01-09 | Immatics Biotechnologies Gmbh | Procédé d'identification de protéines de liaison au cmh et de peptides interagissant dans un échantillon |
| WO2025021979A1 (fr) | 2023-07-27 | 2025-01-30 | Immatics Biotechnologies Gmbh | Nouveaux récepteurs de lymphocytes t ciblant un antigène associé au mélanome (mage) b2 et thérapie immunitaire l'utilisant |
| AU2024300235A1 (en) | 2023-07-27 | 2026-01-08 | Immatics Biotechnologies Gmbh | Antigen binding proteins against mageb2 |
| WO2025040598A2 (fr) | 2023-08-18 | 2025-02-27 | Immatics Biotechnologies Gmbh | Peptides affichés par cmh destinés à être utilisés en immunothérapie contre différents types de cancer |
| WO2025096649A1 (fr) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Il-15 liée à une membrane, polypeptides de cd8, cellules, compositions et leurs procédés d'utilisation |
| WO2025125536A1 (fr) | 2023-12-13 | 2025-06-19 | Immatics Biotechnologies Gmbh | Prédiction du nombre absolu de copies de peptides présentés par le cmh par mesure quantitative relative |
| WO2025125535A1 (fr) | 2023-12-13 | 2025-06-19 | Immatics Biotechnologies Gmbh | Immunopeptidomique différentielle à l'échelle d'une population |
| WO2025233431A1 (fr) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Protéines hétéromères comprenant trois hétéromérisations améliorant la substitution, production, combinaisons et applications associées |
| WO2025233432A1 (fr) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Utilisation et dosage d'une protéine de liaison à l'antigène comprenant un tcr spécifique d'un peptide restreint par hla-a*02 |
| WO2026008886A1 (fr) | 2024-07-05 | 2026-01-08 | Immatics Biotechnologies Gmbh | Moyens et procédés de quantification de l'expression d'une cible |
| WO2026033136A1 (fr) | 2024-08-09 | 2026-02-12 | Immatics Biotechnologies Gmbh | Modalités de traitement avancées pour des cellules immunitaires modifiées par tcr anti-prame |
| WO2026096743A1 (fr) | 2024-10-30 | 2026-05-07 | Immatics US, Inc. | Méthodes de fabrication de cellules t gamma delta |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4290003B2 (ja) | 2001-09-14 | 2009-07-01 | エレクトロフォレティクス リミテッド | 質量標識体 |
| DE10225139A1 (de) | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
| US20050221350A1 (en) * | 2002-05-29 | 2005-10-06 | Toni Weinschenk | Method for identifying immunoreactive peptides |
| US6644103B1 (en) | 2002-10-24 | 2003-11-11 | Simmonds Precision Products, Inc. | Method and apparatus for detecting a dry/wet state of a thermistor bead |
| AU2003277610A1 (en) * | 2002-11-08 | 2004-06-07 | Shuichi Hanada | Method of examining cancer cells and reagent therefor |
| WO2005076009A2 (fr) | 2004-01-28 | 2005-08-18 | Immatics Biotechnologies Gmbh | Procede pour identifier et quantifier des peptides associes aux tumeurs |
| JP2008043332A (ja) * | 2006-08-17 | 2008-02-28 | Panomics Inc | 組織スライドからの核酸定量 |
| RS53782B1 (sr) * | 2008-10-01 | 2015-06-30 | Immatics Biotechnologies Gmbh | Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201006360D0 (en) * | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| EP2697655A2 (fr) | 2011-04-15 | 2014-02-19 | Micromass UK Limited | Procédé et appareil pour l'analyse d'échantillons biologiques |
| WO2012178030A2 (fr) | 2011-06-24 | 2012-12-27 | Applied Isotope Technologies, Inc. | Mesure précise de glutathion dans le diagnostic de maladies et le criblage de métabolites de médicament |
| US10077171B2 (en) * | 2012-10-17 | 2018-09-18 | Grant C. Chustz | Safety barrier for vehicles and cranes |
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| DE102016115246C5 (de) * | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
| KR20250052472A (ko) * | 2017-11-06 | 2025-04-18 | 이매틱스 바이오테크놀로지스 게엠베하 | 신규 조작된 t 세포 수용체 및 이를 사용하는 면역 요법 |
-
2014
- 2014-12-30 GB GBGB1423361.3A patent/GB201423361D0/en not_active Ceased
-
2015
- 2015-12-15 MA MA41287A patent/MA41287B1/fr unknown
- 2015-12-15 KR KR1020177017911A patent/KR102336968B1/ko active Active
- 2015-12-15 MX MX2017008722A patent/MX383806B/es unknown
- 2015-12-15 PL PL15822924T patent/PL3241026T3/pl unknown
- 2015-12-15 HR HRP20210811TT patent/HRP20210811T1/hr unknown
- 2015-12-15 HU HUE15822924A patent/HUE054455T2/hu unknown
- 2015-12-15 SG SG11201703841VA patent/SG11201703841VA/en unknown
- 2015-12-15 PT PT158229245T patent/PT3241026T/pt unknown
- 2015-12-15 ES ES15822924T patent/ES2871035T3/es active Active
- 2015-12-15 CR CR20170297A patent/CR20170297A/es unknown
- 2015-12-15 AU AU2015373584A patent/AU2015373584B2/en active Active
- 2015-12-15 CN CN201580063711.6A patent/CN107003322B/zh not_active Expired - Fee Related
- 2015-12-15 DK DK15822924.5T patent/DK3241026T3/da active
- 2015-12-15 US US14/969,423 patent/US10545154B2/en active Active
- 2015-12-15 LT LTEP15822924.5T patent/LT3241026T/lt unknown
- 2015-12-15 RS RS20210672A patent/RS61914B1/sr unknown
- 2015-12-15 JP JP2017521534A patent/JP6735741B2/ja active Active
- 2015-12-15 WO PCT/EP2015/079873 patent/WO2016107740A1/fr not_active Ceased
- 2015-12-15 EP EP15822924.5A patent/EP3241026B1/fr active Active
- 2015-12-15 BR BR112017008212-8A patent/BR112017008212B1/pt active IP Right Grant
- 2015-12-15 EA EA201791148A patent/EA036328B1/ru unknown
- 2015-12-15 CA CA2972306A patent/CA2972306C/fr active Active
- 2015-12-15 PE PE2017000941A patent/PE20171136A1/es unknown
- 2015-12-15 MA MA40137A patent/MA40137B1/fr unknown
- 2015-12-15 TW TW104142137A patent/TWI632370B/zh not_active IP Right Cessation
- 2015-12-15 UA UAA201701977A patent/UA122774C2/uk unknown
- 2015-12-15 SG SG10201913988XA patent/SG10201913988XA/en unknown
- 2015-12-15 MY MYPI2017700825A patent/MY190199A/en unknown
- 2015-12-15 MD MDE20170252T patent/MD3241026T2/ro unknown
- 2015-12-15 SI SI201531612T patent/SI3241026T1/sl unknown
-
2017
- 2017-03-07 IL IL250982A patent/IL250982B/en active IP Right Grant
- 2017-03-07 ZA ZA2017/01646A patent/ZA201701646B/en unknown
- 2017-03-14 PH PH12017500483A patent/PH12017500483A1/en unknown
- 2017-04-28 CL CL2017001071A patent/CL2017001071A1/es unknown
- 2017-05-05 CO CONC2017/0004543A patent/CO2017004543A2/es unknown
-
2019
- 2019-11-15 US US16/685,765 patent/US11988669B2/en active Active
-
2021
- 2021-06-10 CY CY20211100514T patent/CY1124223T1/el unknown
-
2024
- 2024-04-18 US US18/638,970 patent/US20240280583A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40137B1 (fr) | Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement | |
| Naghavian et al. | Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma | |
| Freire et al. | Human gut derived-organoids provide model to study gluten response and effects of microbiota-derived molecules in celiac disease | |
| Tanoue et al. | A defined commensal consortium elicits CD8 T cells and anti-cancer immunity | |
| Tcyganov et al. | Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy | |
| Chiang et al. | Differential uptake and cross‐presentation of soluble and necrotic cell antigen by human DC subsets | |
| Li et al. | SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer | |
| ZA201901591B (en) | Anti¿muc16 (mucin 16) antibodies | |
| Nelde et al. | Immunopeptidomics-guided warehouse design for peptide-based immunotherapy in chronic lymphocytic leukemia | |
| Vauchy et al. | CD20 alternative splicing isoform generates immunogenic CD 4 helper T epitopes | |
| Durgeau et al. | Human preprocalcitonin self-antigen generates TAP-dependent and-independent epitopes triggering optimised T-cell responses toward immune-escaped tumours | |
| MA43794B1 (fr) | Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie | |
| Calzada-Fraile et al. | Immune synapse formation promotes lipid peroxidation and MHC-I upregulation in licensed dendritic cells for efficient priming of CD8+ T cells | |
| Sekiguchi et al. | MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity | |
| MA40929A (fr) | Procédé de production d'anticorps à affinité élevée | |
| Bear et al. | Natural TCRs targeting KRAS G12V display fine specificity and sensitivity to human solid tumors | |
| BR112021001288A8 (pt) | vacinas individualizadas para câncer | |
| Luo et al. | Berberine increases stromal production of Wnt molecules and activates Lgr5+ stem cells to promote epithelial restitution in experimental colitis | |
| Ng et al. | Enhancing antigen cross-presentation in human monocyte-derived dendritic cells by recruiting the intracellular fc receptor TRIM21 | |
| Sing et al. | Identification of a modulator of the actin cytoskeleton, mitochondria, nutrient metabolism and lifespan in yeast | |
| Rose et al. | Therapeutic anti-glioma effect of the combined action of PCSK inhibitor with the anti-tumoral factors secreted by Poly (I: C)-stimulated macrophages | |
| Marijt et al. | Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement | |
| FI3380115T3 (fi) | Peptidejä piwil1:stä | |
| Kim et al. | Immune checkpoint blockade augments changes within oncolytic virus-induced cancer MHC-I peptidome, creating novel antitumor CD8 T cell reactivities | |
| MX369413B (es) | Peptido. |